Key facts
- This page summarizes Robert Janssen's Form 4 filing for DYNAVAX TECHNOLOGIES CORP (DVAX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Aug 2023, 19:26.
Robert Janssen - 08 Aug 2023 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)
- Reporting relationship
- SVP and CMO
- Issuer ticker
- DVAX
- Reported as of
- 08 Aug 2023
- Net transaction value
- -$14,664
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2023, 19:26:52 UTC
- Prior SEC filing
- 01 Mar 2023
- Next SEC filing
- 24 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Janssen
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Janssen filed Form 4 for DYNAVAX TECHNOLOGIES CORP (DVAX) on 09 Aug 2023.
Change
- Previous filing in this sequence was filed on 01 Mar 2023.
- Current net transaction value: -$14,664.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DVAX
transaction
Common Stock
Options Exercise
- Transaction value
- $24,466
- Shares
- +2,600
- Change %
- +5.2%
- Price
- $9.41
- Shares after
- 52,525
- Date
- 08 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
DVAX
transaction
Common Stock
Sale
- Transaction value
- $39,130
- Shares
- -2,600
- Change %
- -5%
- Price
- $15.05
- Shares after
- 49,925
- Date
- 08 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DVAX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -2,600
- Change %
- -3.1%
- Price
- Shares after
- 82,400
- Date
- 08 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,600
- Exercise price
- $9.41
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 14, 2023.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $15.00 to $15.10; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
Footnote F3
This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
Footnote F4
Not applicable.